MAPT and Alzheimer disease: Through the sampling of CSF, it is possible to detect AD‐relevant changes including changes to the levels of Aβ40 or Aβ42,18 the Aβ40/42 ratio,11, 12 total tau (t‐tau) levels19 and phosphorylated tau (p‐tau) levels.20